Journal article icon

Journal article

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Abstract:

BACKGROUND: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1159/000212671

Authors


Journal:
Cerebrovascular diseases (Basel, Switzerland) More from this journal
Volume:
27
Issue:
5
Pages:
509-518
Publication date:
2009-01-01
DOI:
EISSN:
1421-9786
ISSN:
1015-9770

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP